Olr3 inhibitors represent a class of compounds characterized by their ability to selectively inhibit the activity of the Olr3 protein, a member of the olfactory receptor family. Olr3, or Olfactory Receptor 3, is part of the G-protein-coupled receptor (GPCR) superfamily, which is widely involved in the detection of chemical signals and the transduction of these signals into cellular responses. These receptors are primarily known for their role in the olfactory system, where they contribute to the detection of volatile compounds and the perception of smell. However, Olr3, like many other olfactory receptors, is also expressed in various tissues outside the olfactory epithelium, suggesting it may play broader roles in cellular signaling. The precise physiological functions of Olr3 are still being elucidated, but its inhibition could potentially modulate various cellular processes linked to this receptor.
The chemical structures of Olr3 inhibitors are diverse, reflecting the varied approaches in designing molecules that can effectively bind to and inhibit the Olr3 receptor. These inhibitors typically interact with the receptor's binding site, either competitively or non-competitively, thereby preventing the receptor from undergoing the conformational changes necessary for signal transduction. The structural complexity of Olr3 and its inhibitors often involves intricate stereochemistry and specific molecular interactions, such as hydrogen bonding, hydrophobic interactions, and van der Waals forces, which contribute to the selectivity and potency of the inhibition. The study of Olr3 inhibitors not only enhances the understanding of this specific receptor's role in cellular communication but also contributes to broader research on the function of GPCRs in various physiological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist, might modulate GPCR activity, potentially affecting Olr3. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking activity, could influence Olr3 signaling. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, may affect GPCR signaling pathways related to Olr3. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Combined alpha and beta blocker, could indirectly affect GPCR pathways, including Olr3. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, may influence GPCR-mediated signaling pathways related to Olr3. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist, could indirectly affect Olr3 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, may influence GPCR signaling pathways including Olr3. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr3. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Beta blocker, could indirectly influence GPCR signaling pathways including Olr3. | ||||||